# US 8,278,264 B2 · Compositions and methods for enhancing drug delivery across and into ocular tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,264 B2
- Document ID: US8278264B2
- Status: Granted
- Kind: B2
- Application number: 11/800,358
- Filed: 2007-05-04
- Published: 2007-09-13
- Granted: 2012-10-02
- Earliest claimed: 1999-08-24
- Assignees: KAI Pharmaceuticals, Inc.
- Inventors: Jonathan B. Rothbard; Paul A. Wender; P. Leo McGrane; Lalitha V. S. Sista; Thorsten A. Kirschberg
- Web page: https://patentgrep.com/patent/US8278264B2

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61K 47/557: {the modifying agent being biotin}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/665: {the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/085: {conjugated systems}
- A61K 49/146: {the peptide being a polyamino acid, e.g. poly-lysine}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (for example, SEQ ID NO:86).

## Claims

### Claim 1

A method for enhancing delivery of a compound into and across an animal ocular tissue, the method comprising:
administering to the ocular tissue a conjugate comprising the compound and a delivery-enhancing transporter,
wherein the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties, thereby increasing delivery of the conjugate into the ocular tissue compared to delivery of the compound in the absence of the delivery-enhancing transporter.

### Claim 2 (depends on 1)

The method of claim 1, wherein delivery of the conjugate into the ocular tissue is increased at least two-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter.

### Claim 3 (depends on 1)

The method of claim 1, wherein delivery of the conjugate into the ocular tissue is increased at least ten-fold compared to delivery of the compound in the absence of the delivery-enhancing transporter.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ocular tissue is one or more layers of epithelial or endothelial tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ocular tissue is the retina.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ocular tissue is the optic nerve.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subunits are amino acids.

### Claim 8 (depends on 1)

The method of claim 1, wherein the conjugate comprises at least two delivery-enhancing transporters.

### Claim 9 (depends on 1)

The method of claim 1, wherein the conjugate is administered as an eye drop.

### Claim 10 (depends on 1)

The method of claim 1, wherein the conjugate is administered as an injection.

### Claim 11 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter comprises a non-peptide backbone.

### Claim 12 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter is not attached to an amino acid sequence to which the delivery enhancing transporter molecule is attached in a naturally occurring protein.

### Claim 13 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties.

### Claim 14 (depends on 13)

The method of claim 13, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties.

### Claim 15 (depends on 13)

The method of claim 13, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties.

### Claim 16 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the delivery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein at least one arginine is a D-arginine.

### Claim 19 (depends on 18)

The method of claim 18, wherein all of the arginines are D-arginines.

### Claim 20 (depends on 16)

The method of claim 16, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs.

### Claim 21 (depends on 16)

The method of claim 16, wherein the delivery-enhancing transporter is seven contiguous D-arginines.

### Claim 22 (depends on 1)

The method of claim 1, wherein the compound is a therapeutic for a disease selected from the group consisting of bacterial infections, viral infections, fungal infections, glaucoma, anterior uveitis, intermediate uveitis, posterior uveitis, optic neuritis, Leber's neuroretinitis, retinitis, pseudotumor/myositis, orbital myositis, hemangioma/lymphangioma, toxocariasis, Behcet's panuveitis, inflammatory chorioretinopathies, vasculitis, dry eye syndrome (Sjögren's syndrome), corneal edema, accommodative esotropia, cycloplegia, mydriasis, reverse mydriasis, and macular degeneracy.

### Claim 23 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of anti-bacterial compounds, anti-viral compounds, anti-fungal compounds, anti-protozoan compounds, anti-histamines, compounds that dilate the pupil, anesthetic compounds, steroidal antiinflammatory agents, antiinflammatory analgesics, chemotherapeutic agents, hormones, anticataract agents, neovascularization inhibitors, immunosuppressants, protease inhibitors, aldose reductase inhibitors, corticoid steroids, cholinergic agents, anticholinesterase agents, muscarinic antagonists, sympathomimetic agents, alpha-adrenergic antagonists, beta-adrenergic antagonists, and anti-angiogenic factors.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound is selected from the group consisting of acyclovir and cyclosporins.

### Claim 25 (depends on 1)

The method of claim 1, wherein the compound is transported across the blood-brain barrier.

### Claim 26 (depends on 1)

The method of claim 1, wherein the ocular tissue is one or more layers of epithelial and one or more layers of endothelial tissue.

### Claim 27 (depends on 1)

The method of claim 1, wherein the ocular tissue is one or more layers of epithelial tissue.

### Claim 28 (depends on 1)

The method of claim 1, wherein the ocular tissue is one or more layers of endothelial tissue.
